Technology transfer

Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain

Retrieved on: 
Monday, January 10, 2022
Health, Pain, Alzheimer's disease, U.S. Securities and Exchange Commission, Annual report, Program, Partnership, Migraine, European Investment Fund, Tic disorder, FDA, Technology transfer, Pain management, TRP, Ion, Security (finance), Board, Student, Science, Center, MPO, Private Securities Litigation Reform Act, Company, Doctor of Philosophy, Drug design, Chronic pain, Analgesic, Transient receptor potential channel, Pain disorder, Amyotrophic lateral sclerosis, Drug discovery, Patient, Takeda Pharmaceutical Company, Research, Therapy, Transience, NYSE, News, Intellectual property, LICR, Disease, Risk, LRD, Industry, Spinocerebellar ataxia, CGRP, CD3, TRPM3, Pharmaceutical industry, Dentistry, HAVEN, KU Leuven, Development

TRPM3 is a cation channel involved in pain signaling and a novel target for the treatment of pain discovered at KU Leuven's LICR.

Key Points: 
  • TRPM3 is a cation channel involved in pain signaling and a novel target for the treatment of pain discovered at KU Leuven's LICR.
  • There is an urgent unmet need for safe, effective treatments for pain, and TRPM3 antagonism is a promising approach to advance new pain therapies.
  • Under the agreement, Biohaven Therapeutics receives exclusive global rights to develop, manufacture and commercialize KU Leuven's small-molecule TRPM3 antagonists.
  • Biohaven Therapeutics will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders.

OcyonBio Appoints Robert Salcedo as Chief Executive Officer

Retrieved on: 
Thursday, January 6, 2022
Ecosystem, CGMP, Research, Patient, CMC, Technology transfer, Goal, Culture, FDA, Partnership, LLC, GLOBE, Industry, Pharmaceutical industry, Biotechnology

OcyonBio will provide preclinical through commercial manufacturing, including process development, viral vectors, cell banking, cell processing, and supporting testing capabilities.

Key Points: 
  • OcyonBio will provide preclinical through commercial manufacturing, including process development, viral vectors, cell banking, cell processing, and supporting testing capabilities.
  • Robert Salcedo has 25+ years of experience in Biotechnology and Solid Dose Manufacturing experience, which includes 7+ years of working closely with start-ups in gene and cell therapy companies.
  • He led executive teams in Developing Regulatory, CMC, Clinical, and manufacturing scale-up strategies and constructing commercial facilities ranging from $20MM to $1.5Bn.
  • I am laser-focused on building a company that will solve the biggest challenge in cell and gene therapy development, which is high-quality manufacturing," said Robert Salcedo.

Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark License Agreement

Retrieved on: 
Wednesday, January 5, 2022
Software, Physical Therapy, Hardware, Health, Medical Devices, Technology, Other Technology, Other Health, JV, Amend, Brachial plexus injury, Company, Patient, Arm, Stroke, NYSE, Lists of diseases, Technology transfer, Ascending limb of loop of Henle, Risk, U.S. Securities and Exchange Commission, Security (finance), Private Securities Litigation Reform Act, CEO, EMG, Compliance, Neuromuscular disease, Technology, ALS, CVA, Effective date, Paralysis, Pharmaceutical industry

The Amended JV Agreement, the Technology License Agreement and the Trademark License Agreement are each effective December 29, 2021 (the Effective Date).

Key Points: 
  • The Amended JV Agreement, the Technology License Agreement and the Trademark License Agreement are each effective December 29, 2021 (the Effective Date).
  • The original Joint Venture Agreement was entered into on January 21, 2021.
  • Under the Amended JV Agreement, Myomo will continue to own a 19.9% stake in the JV Company.
  • The technology transfer to the JV Company will begin after receipt of the full license fee, which is expected before the end of the first quarter of 2022.

VETIGENICS ANNOUNCES PUBLICATION OF COMPREHENSIVE PRECLINICAL DATA FOR ANTI-CANINE CTLA4 MONOCLONAL ANTIBODY

Retrieved on: 
Wednesday, January 5, 2022
University, Safety, Strategic planning, Veterinary medicine, CD80, PETS, Doctor of Philosophy, Mab, Review, Therapy, Ligand, Immune system, Physician, CTLA4, Technology transfer, Mouse, Cancer, Science, MD, LinkedIn, Manuscript, Antibody, SMILES arbitrary target specification, Human, Half-life, Technology, Risk, Immunotherapy, Animal, Neutralizing antibody, Friends, CD86, Vaccine, Dog

The manuscript, "Development of a Fully Canine Anti-Canine CTLA4 Monoclonal Antibody for Comparative Translational Research in Dogs with Spontaneous Tumors," describes the discovery, design and functional properties of this important immune checkpoint inhibitor.

Key Points: 
  • The manuscript, "Development of a Fully Canine Anti-Canine CTLA4 Monoclonal Antibody for Comparative Translational Research in Dogs with Spontaneous Tumors," describes the discovery, design and functional properties of this important immune checkpoint inhibitor.
  • It also validates the use of Vetigenics' proprietary phage display libraries to rapidly isolate and evaluate novel, entirely canine antibodies.
  • "The results of this work are compelling," said Vetigenics co-founder Nicola Mason, BVetMD, PhD.
  • "We've proven Vetigenics' unique platform and developed a novel veterinary checkpoint inhibitor that's specific for its target and promotes T cell responses.

Aspira Women’s Health Executes an Agreement with Axia Women’s Health to Launch Aspira Synergy Genetics Platform

Retrieved on: 
Wednesday, January 5, 2022
Intelligence, Health, Ovarian cancer, Chemistry, Genetic testing, Patient, Fertility, Genetics, Axia, Physician, Â, Technology transfer, Acıbadem Healthcare Group, Obstetrics, Compte rendu, Laboratory, NGS, Annual report, Private Securities Litigation Reform Act, Gynaecology, Mammography, Risk assessment, CEO, Biochemistry, FDA, Woman, Partnership, GLOBE, Risk, FACMG, Nasdaq, Cancer, Solution, Endometriosis, DNA sequencing, Pharmaceutical industry, Medical device, Medicine, Aspira

Axia Womens Health is an innovative and progressive community of more than 400 providers and 150 womens health centers across New Jersey, Pennsylvania, Indiana, Ohio, and Kentucky.

Key Points: 
  • Axia Womens Health is an innovative and progressive community of more than 400 providers and 150 womens health centers across New Jersey, Pennsylvania, Indiana, Ohio, and Kentucky.
  • Under the five-year agreement, Axia Womens Health providers will have the ability to conduct genetic testing in-house utilizing the proprietary Aspira Synergy Genetics platform.
  • The Aspira Synergy Genetics solution can generate these customized, high-quality clinical genetics reports for the laboratory, referring physicians, and patients.
  • We are very excited to offer our groundbreaking global technology to Axia Womens Health, one of the nations top womens health networks.

Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic

Retrieved on: 
Tuesday, January 4, 2022
Safety, CGMP, ITG, U.S. Securities and Exchange Commission, MSA, Deepak Nitrite, Neoplasm, Cancer, Technology transfer, GLOBE, Glioblastoma, Company, Perception, Chemistry, Food, Radiation, Dow Chemical Company, Intellectual property, Therapy, Research, PSTV, Patient, Nasdaq, Radiopharmaceutical, Liposome, Good manufacturing practice, Technology, PPS, Food and Drug Administration, Pharmaceutical industry

AUSTIN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it has met two significant milestones as it progresses toward cGMP manufacture of Rhenium-186 NanoLiposome (186RNL).

Key Points: 
  • The Company has entered into a master services agreement (MSA) with IsoTherapeutics Group LLC for the development, manufacture and supply of current Good Manufacturing Practices (cGMP) grade Rhenium-186 isotope for the Companys 186RNL investigational radiotherapeutic.
  • Under the MSA, IsoTherapeutics will develop a synthesis process and in-process manufacturing controls, test method development and validation, stability studies, as well as manufacture cGMP Rhenium-186.
  • Additionally and importantly, Plus Therapeutics completed the technology transfer of analytical test methods with Piramal Pharma Solutions (PPS) for 186RNL drug product intermediate.
  • As previously disclosed , Plus Therapeutics entered into a MSA with PPS in early 2021 for the development, manufacture and supply of Plus Therapeutics 186RNL intermediate drug product.

GC Cell Inks First Licensing Agreement for Immuncell-LC® With Rivaara Immune Private Limited in India

Retrieved on: 
Tuesday, January 4, 2022
Biotechnology, Health, Stem Cells, Pharmaceutical, Oncology, Korean, Bharat, B cell, Immunotherapy, Cancer, Technology transfer, MFDS, Survival, Treatment, Quality of life, Partnership, Pancreatic cancer, Liver cancer, CEO, Achievement, Patient, Technology, Blood, Vaccine, Security (finance), Pharmaceutical industry, Immuncell-LC®, GC Cell, Rivaara Immune Private Limited, IMMUNCELL-LC®, GC CELL, RIVAARA IMMUNE PRIVATE LIMITED

GC Cell (KOSDAQ:144510) and Rivaara Immune Private Limited today announced that they have entered into an exclusive licensing agreement, pursuant to which Rivaara Immune has agreed to develop and commercialize Immuncell-LC in India, Sri Lanka, and Bangladeshi.

Key Points: 
  • GC Cell (KOSDAQ:144510) and Rivaara Immune Private Limited today announced that they have entered into an exclusive licensing agreement, pursuant to which Rivaara Immune has agreed to develop and commercialize Immuncell-LC in India, Sri Lanka, and Bangladeshi.
  • Under the terms of the agreement, Rivaara Immune has obtained the exclusive right to develop and commercialize Immuncell-LC within India for liver cancer.
  • Immuncell-LC's overseas expansion is based on its domestic success, pushing for technology transfer by country, and signing contract with Rivaara Immune in India is the first outcome, said Dae-woo Park, CEO of GC Cell.
  • Rivaara Immune is pleased to partner with GC Cell, a leader in Immune Cell Therapy in Korea.

Neom Coin to be Listed on BitMart on January 6

Retrieved on: 
Monday, January 3, 2022
People, Social media, Graphene, Technology transfer, World, City, Internet, Company, Solution, RFID, Artificial intelligence, Intelligence, Technology, World Bank, Common, NFT, Network, Creation, C, Industry, Cryptocurrency, Insurance, Blockchain, Metaverse, Migrant

We were inspired by the word Neom, meaning 'New Future', as we developed a cryptocurrency called Neom Coin, which will be listed on BitMart cryptocurrency exchange on January 6, 2022.

Key Points: 
  • We were inspired by the word Neom, meaning 'New Future', as we developed a cryptocurrency called Neom Coin, which will be listed on BitMart cryptocurrency exchange on January 6, 2022.
  • Given these circumstances, there is a gap in this need, and Neom Blockchain Technologies is ambitious to fill this gap with Neom Coin.
  • On Thursday, January 6, Neom Coin will begin its journey on the BitMart cryptocurrency exchange.
  • We invite visitors to Neom Blockchain Technology and Neom Coin by following these links to the official social media accounts:

BioMe Inc. and Yonsei Medical Center Sign Technology Transfer Contract for Pathbreaking Microbiome Treatment

Retrieved on: 
Wednesday, December 29, 2021
Department, Clinical trial, Technology transfer, GLOBE, Yonsei University, Research, Biome, Therapy, LBP, Immunology, Pharmaceutical industry, Microbiology

However, recent clinical trial failure reports and the limitation to identify a clear mode of action demand a careful approach.Korea-based company BioMe Inc. wants to bring in disruption with pathbreaking microbiome-based therapeutics.

Key Points: 
  • However, recent clinical trial failure reports and the limitation to identify a clear mode of action demand a careful approach.Korea-based company BioMe Inc. wants to bring in disruption with pathbreaking microbiome-based therapeutics.
  • To accelerate its research & development process, the startup recently signed a technology transfer contract with Yonsei University College of Medicine.
  • BioMe Inc. would start developing microbiome-based therapeutics with the six patents transferred from Yonsei University College of Medicine.
  • The technology transfer under the contract includes a total of six patents, and BioMe's development pipeline is as follows:

Baylor Genetics and SRL, Inc. Initiate Clinical Grade of Whole Exome and Genome Sequencing Technology Transfer

Retrieved on: 
Wednesday, December 29, 2021
National, Spotless Group Holdings, Baylor University, R&D, WES, Technology transfer, LLC, Medical research, BG, No, GLOBE, Texas Medical Center, Genetic testing, Partnership, CEO, NIH, CMO, R, Precision medicine, LTS, Patient, Whole genome sequencing, WGS, Japan Agency for Medical Research and Development, Exome sequencing, Technology, SRL, Genetics, D, Baylor College of Medicine, Pharmaceutical industry

"I am confident that this collaboration enables SRL to provide optimal clinical sequencing for Japanese patients by applying the world's best technology with Baylor Genetics," said Kazuya Omi, R&D Executive Officer at SRL.

Key Points: 
  • "I am confident that this collaboration enables SRL to provide optimal clinical sequencing for Japanese patients by applying the world's best technology with Baylor Genetics," said Kazuya Omi, R&D Executive Officer at SRL.
  • As part of the agreement, BG will transfer its knowledge of WES and WGS as clinical services to SRL with technical support to enhance the Japanese lab's capabilities.
  • The technology transfer is expected to start in 2022 with efforts to contribute towards precision medicine application in Japan.
  • To learn more about Baylor Genetics' Whole Exome Sequencing services, visit: https://www.baylorgenetics.com/whole-exome-sequencing/
    To learn more about Baylor Genetics' Whole Genome Sequencing services, visit: https://www.baylorgenetics.com/whole-genome-sequencing/